hepatitis D

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

China clears its first drug for chronic hepatitis D

Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.

News

Bluejay hatches $182m funding egg for hepatitis drugs

Bluejay Therapeutics has completed a sizeable third-round financing, raising $182 million that will be used for clinical trials of its drug candidates for hepatitis.

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

News

After FDA rejection, Gilead nears full EU nod for hep D drug

Gilead Sciences is on the brink of getting full approval for the first drug for hepatitis D virus (HDV) in the EU, after getting a positive opinion from the EMA’s human me

News

The diagnosis Hepatitis written on a clipboard

FDA rejects Gilead's hepatitis D therapy Hepcludex

Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application.

Gilead claims first FDA nod for a hepatitis D therapy

China clears its first drug for chronic hepatitis D

Bluejay hatches $182m funding egg for hepatitis drugs

Eiger wields axe as FDA sets high bar for hepatitis drug

After FDA rejection, Gilead nears full EU nod for hep D drug

FDA rejects Gilead's hepatitis D therapy Hepcludex

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

hepatitis D

Editor's Picks